Open Payments

Newyork-Presbyterian/Queens

Type
Teaching hospital
Where
Flushing, NY
Medicare CCN
330055
Received
$346,019 in 50 records, 2025 ($192,646 general, $153,373 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment21$192,646
2025Research payment29$153,373

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.3$163,9622025
Janssen Research & Development, LLC13$56,1962025
Novartis Pharmaceuticals Corporation5$28,8872025
Boston Scientific Corporation4$27,9722025
ENDOTRONIX, INC.1$16,6832025
Siemens Medical Solutions USA, Inc.2$14,3032025
Humacyte Global, Inc.3$5,6172025
Stryker Corporation5$4,4362025
Volta Medical Inc1$4,2502025
SUVON SURGICAL LLC1$3,0002025
BIOTRONIK INC.2$2,5532025
E.R. Squibb & Sons, L.L.C.1$2,5002025
Edwards Lifesciences Corporation1$2,5002025
Abbott Laboratories1$2,5002025
AstraZeneca Pharmaceuticals LP1$2,5002025
Boehringer Ingelheim Pharmaceuticals, Inc.1$2,5002025
Biosense Webster, Inc.1$2,5002025
PFIZER INC.1$1,9632025
Penumbra, Inc.1$1,0002025
Zimmer Biomet Holdings, Inc.1$1212025
Baxter Healthcare1$732025

By nature of payment

NatureRecordsAmount
Grant5$167,462
Research payment29$153,373
Space rental or facility fees (teaching hospital only)9$19,000
Debt forgiveness6$3,684
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$2,500

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$3,243Debt forgivenessCash or cash equivalent2025
2025-12-31Stryker Corporation$170Debt forgivenessCash or cash equivalent2025
2025-12-31BIOTRONIK INC.$53Debt forgivenessCash or cash equivalent2025
2025-12-31Stryker Corporation$21Debt forgivenessCash or cash equivalent2025
2025-12-15Janssen Research & Development, LLC$6,237Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-11-21Janssen Research & Development, LLC$4,053Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-11-17Novartis Pharmaceuticals Corporation$1,869Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesA Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-10-27Novartis Pharmaceuticals Corporation$20Research paymentIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular DiseasesA Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-10-22Janssen Research & Development, LLC$3,900Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-10-09Humacyte Global, Inc.$2,726Research paymentCash or cash equivalentSymvess Biological, Extremity Arterial InjuryTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi2025
2025-10-08Humacyte Global, Inc.$1,308Research paymentCash or cash equivalentSymvess Biological, Extremity Arterial InjuryTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi2025
2025-09-23Baxter Healthcare$73Debt forgivenessIn-kind items and services2025
2025-09-19Janssen Research & Development, LLC$4,785Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-09-10PFIZER INC.$1,963Research paymentCash or cash equivalentTIVDAK Biological, ONCOLOGYA RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RE2025
2025-08-25Janssen Research & Development, LLC$3,900Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-08-25Humacyte Global, Inc.$1,581Research paymentCash or cash equivalentSymvess Biological, Extremity Arterial InjuryTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi2025
2025-07-25Novartis Pharmaceuticals Corporation$12,524Research paymentCash or cash equivalentA Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND St2025
2025-07-14Janssen Research & Development, LLC$6,895Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-07-08Gilead Sciences, Inc.$92,823GrantCash or cash equivalent2025
2025-07-08Boston Scientific Corporation$14,172Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMLUX-DX TRENDS2025
2025-06-30Zimmer Biomet Holdings, Inc.$121Debt forgivenessCash or cash equivalent2025
2025-06-25Janssen Research & Development, LLC$1,957Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-06-20Janssen Research & Development, LLC$4,868Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-06-18Abbott Laboratories$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentJETI PERIPHERAL CATHETER Device, Vascular2025
2025-06-17Boston Scientific Corporation$10,250Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMADVENT PAS2025
2025-06-17Volta Medical Inc$4,250Research paymentCash or cash equivalentAF-Xplorer Device, DevicesCOMPANION AI2025
2025-05-27Gilead Sciences, Inc.$61,039GrantCash or cash equivalent2025
2025-05-27Gilead Sciences, Inc.$10,100GrantCash or cash equivalent2025
2025-05-23Janssen Research & Development, LLC$1,524Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-05-22Penumbra, Inc.$1,000GrantCash or cash equivalent2025
2025-05-15BIOTRONIK INC.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-05-08Edwards Lifesciences Corporation$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-05-08Stryker Corporation$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentVSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL2025
2025-05-08Stryker Corporation$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentDURACON Device, KNEES2025
2025-05-07Boston Scientific Corporation$2,500GrantIn-kind items and servicesGeneral - EP Device, General - EP_EP2025
2025-05-02Novartis Pharmaceuticals Corporation$2,018Research paymentCash or cash equivalentA Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND St2025
2025-04-23Janssen Research & Development, LLC$3,226Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-03-25Biosense Webster, Inc.$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentCARTO 3 Device, Cardiology2025
2025-03-17Siemens Medical Solutions USA, Inc.$5,400Research paymentCash or cash equivalentADVIA Centaur XP Analyzer Device, DX - Diagnostics incl. all products and servicesPE OUS STUDY2025
2025-03-17Janssen Research & Development, LLC$3,811Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-03-14Siemens Medical Solutions USA, Inc.$8,903Research paymentCash or cash equivalentADVIA Centaur XP Analyzer Device, DX - Diagnostics incl. all products and servicesPE OUS STUDY2025
2025-03-14AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-03-12Boehringer Ingelheim Pharmaceuticals, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-03-06E.R. Squibb & Sons, L.L.C.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-02-27Novartis Pharmaceuticals Corporation$12,454Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesA Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-02-25SUVON SURGICAL LLC$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-02-24Janssen Research & Development, LLC$1,616Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-02-21ENDOTRONIX, INC.$16,683Research paymentCash or cash equivalentCORDELLA PULMONARY ARTERY PRESSURE SENSOR Device, HEART FAILUREPROACTIVE-HF2025
2025-01-28Boston Scientific Corporation$1,050Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMLUX-DX TRENDS2025
2025-01-22Janssen Research & Development, LLC$9,424Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New York; placed by its state only.

MeasureState
New York
Population B0100319,852,366
Population, 2020 census P120,201,249
Median age B0100239.8
Under 18 B0100120.5%
65 and over B0100117.9%
Households B110017,722,646
Foreign born B0500222.8%
Median household income B19013$85,974
Median family income B19113$106,873
Per capita income B19301$50,712
Poverty rate B1700114.0%
Unemployment rate B230256.4%
Civilian labor force B2302510,171,766
Mean commute (minutes) B0801332.6
Bachelor's degree or higher B1500340.2%
Housing units B250018,585,241
Owner-occupied B2500354.3%
Renters B2500345.7%
Median home value B25077$423,800
Median gross rent B25064$1,621
White, not Hispanic B0300252.8%
Black B0300213.4%
Hispanic or Latino B0300219.8%
Asian B030029.0%
American Indian and Alaska Native B030020.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.